Anesthesiology · 2011 · 43 citations · 39 references
Life SciencesCardiologyImmunologyCell SignalingInnate ImmunitySignal TransductionInflammatory SignalingInnate Immune ResponseInnate Immune Signaling PathwaysIschemic Heart DiseaseMyocardial ProtectionToll-like ReceptorsIntracellular Signaling PathwaysMyd88-dependent SignalingMyeloid Differentiation Primary Response 88 SignalingMyocardial Ischemia-reperfusion InjuryNitric OxideNitric Oxide ProductionToll-like Receptor SignalingToll-like Receptor-mediated Innate Immune Response
BACKGROUND: Prior administration of a small dose of lipopolysaccharide confers a cardiac protection against ischemia-reperfusion injury. However, the signaling mechanisms that control the protection are incompletely understood. We tested the hypothesis that Toll-like receptor 4 (TLR4) mediates the ability of lipopolysaccharide to protect against cardiac ischemia-reperfusion injury through distinct intracellular pathways involving myeloid differentiation factor 88 (MyD88), TIR-domain-containing adaptor protein-inducing interferon-β-mediated transcription factor (Trif), inducible nitric oxide synthase (iNOS), and soluble guanylate cyclase (sGC). METHODS: Wild-type mice and genetically modified mice, that is TLR4-deficient (TLR4(-def)), TLR2 knockout (TLR2(-/-)), MyD88(-/-), Trif(-/-), iNOS(-/-), and sGCα1(-/-), were treated with normal saline or 0.1 mg/kg lipopolysaccharide intraperitoneally. Twenty-four hours later, isolated hearts were perfused in a Langendorff apparatus and subsequently subjected to 30 min global ischemia and reperfusion for as long as 60 min. Left ventricular function and myocardial infarction sizes were examined. RESULTS: Compared with saline-treated mice, lipopolysaccharide-treated mice had markedly improved left ventricular developed pressure and dP/dt(max) (P < 0.01) and reduced myocardial infarction sizes (37.2 ± 3.4% vs. 19.8 ± 4.9%, P < 0.01) after ischemia-reperfusion. The cardiac protective effect of lipopolysaccharide was abolished in the TLR4(-def) and MyD88(-/-) mice but remained intact in TLR2(-/-) or Trif(-/-) mice. iNOS(-/-) mice or wild-type mice treated with the iNOS inhibitor 1400W failed to respond to the TLR4-induced nitric oxide production and were not protected by the lipopolysaccharide preconditioning. Although sGCα(1)(-/-) mice had robust nitric oxide production in response to lipopolysaccharide, they were not protected by the TLR4-elicited cardiac protection. CONCLUSIONS: TLR4 activation confers a potent cardiac protection against ischemia-reperfusion injury via a MyD88-dependent, but Trif-independent, mechanism. iNOS/sGC are essential for the TLR4-induced cardiac protection.
39
Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in <i>Tlr4</i> Gene
Alexander Poltorak, Xiaolong He, Irina Smirnova et al. · Science · 1998 · 7.6K citations
Role of Adaptor TRIF in the MyD88-Independent Toll-Like Receptor Signaling Pathway
Masahiro Yamamoto, Shintaro Sato, Hiroaki Hemmi et al. · Science · 2003 · 3.2K citations
Unresponsiveness of MyD88-Deficient Mice to Endotoxin
Taro Kawai, Osamu Adachi, Tomohiko Ogawa et al. · Immunity · 1999 · 2.1K citations · Full text